Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC
Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.
EP: 1.Molecular Testing in Advanced NSCLC
EP: 2.T-DXd in HER2 Mutated Advanced NSCLC
EP: 3.Dato-DXd for Treating Advanced NSCLC
EP: 4.Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC
Now Viewing
EP: 5.Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC
EP: 6.Future Perspectives in ADCs for Treating Advanced NSCLC
EP: 7.Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC
EP: 8.Increasingly Targeted ADCs Drive NSCLC Treatment Innovations
Related Videos
Related Content
